CLVS Clovis Oncology Inc.

8.93
-0.28  -3%
Previous Close 9.21
Open 9.28
Price To Book -5.58
Market Cap 647,891,463
Shares 72,592,881
Volume 9,972,513
Short Ratio
Av. Daily Volume 12,798,017
Stock charts supplied by TradingView

NewsSee all news

  1. Clovis Oncology's Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer

    - Clovis seeks U.S. approval for rucaparib as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer - FDA submission based on data from TRITON clinical program

  2. Clovis Oncology Announces Debt Refinancing Transaction

    Clovis Oncology, Inc. (NASDAQ:CLVS) (the "Company") announced today that on January 6, 2020 it priced a registered direct offering (the "Share Offering") of an aggregate of 17,777,679 shares (the "Shares") of its common

  3. Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019

    Estimated $38.3M - $39.3M in Rubraca® sales for Q4 2019 and $142.0M-$143.0M for FY2019 consistent with guidance Q4/FY2019 Operating Results call planned for

  4. Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium

    Presented at the International Symposium on Theranostics/Precision Oncology (ICPO) FAP-targeted images consistent with those of PET and CT scans Encouraging tumor accumulation and retention in initial

  5. Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy

    Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type Rucaparib

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date under priority review May 15, 2020.
Rubraca (rucaparib)
Castrate-resistant prostate cancer (mCRPC)
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrolment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Approval announced April 6, 2018.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Rociletinib
Mutant EGFR T790M-positive lung cancer
Development discontinued
Lucitanib
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line
Phase 2 trial to be discontinued due to lack of efficacy - April 12, 2019.
Rucaparib - ATLAS
Urothelial carcinoma
ESMO presentation at ESMO October 2018.
Lucitanib
HR+ Her2- metastatic breast cancer
Phase 3 confirmatory trial is enrolling.
Rucaparib ARIEL4
Relapsed ovarian cancer patients with BRCA mutations
Phase 2 data presented at AACR April 2019. PFS 9.1 months.
Rucaparib
Platinum-sensitive pancreatic cancer
Phase 1b/2 initial data due at ASCO June 2020.
Lucitanib with Opdivo
Solid tumors
Phase 1/2 trial underway.
Lucitanib with Rubraca (SEASTAR)
Ovarian cancer

Latest News

  1. Clovis Oncology's Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer

    - Clovis seeks U.S. approval for rucaparib as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer - FDA submission based on data from TRITON clinical program

  2. Clovis Oncology Announces Debt Refinancing Transaction

    Clovis Oncology, Inc. (NASDAQ:CLVS) (the "Company") announced today that on January 6, 2020 it priced a registered direct offering (the "Share Offering") of an aggregate of 17,777,679 shares (the "Shares") of its common

  3. Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019

    Estimated $38.3M - $39.3M in Rubraca® sales for Q4 2019 and $142.0M-$143.0M for FY2019 consistent with guidance Q4/FY2019 Operating Results call planned for

  4. Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium

    Presented at the International Symposium on Theranostics/Precision Oncology (ICPO) FAP-targeted images consistent with those of PET and CT scans Encouraging tumor accumulation and retention in initial

  5. Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy

    Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type Rucaparib

  6. Clovis Oncology Announces Third Quarter 2019 Operating Results

    $37.6M in Rubraca® (rucaparib) net product revenue for Q3 2019, up 65% year over year Net product revenue increased 14% sequentially in Q3 2019 compared to Q2 2019, including sequential U.S. sales increase of 12%

  7. Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7

    Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its third quarter 2019 financial results on Thursday, November 7, 2019, before the open of the U.S. financial markets. Clovis' senior management will host a conference

  8. Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund

    Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through

  9. Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019

    43.9% confirmed objective response rate (ORR) in 57 RECIST*-evaluable patients with metastatic castration-resistant prostate cancer (mCRPC) and a BRCA1/2 mutation 52.0% confirmed prostate-specific antigen (PSA)

  10. Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

    Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy Clovis to pay approximately $12 million in upfront payments to 3B Pharmaceuticals Clovis currently planning to

  11. Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019

    Updated data from the Phase 2 TRITON2 trial of Rubraca in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) Exploratory ARIEL3 analysis for Rubraca maintenance treatment regimen in

  12. Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference

    Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 2019 Wells Fargo Healthcare Conference on Thursday, September 5, 2019 at 8:35 AM

  13. Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company's 4.50% Convertible Senior Notes Due 2024

    Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the initial purchasers of the previously announced offering of the Company's 4.50% Convertible Senior Notes due 2024 (the "notes") in a private placement to